PONDx breast cancer recurrence score: a significant adjunct to standard parameters and its role in reducing the uptake of chemotherapy. A single centre experience.
Association of Breast Surgery ePoster Library. JAMES M. 05/13/19; 257187; P145
Magnus JAMES
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P145
Topic: Risk factors for breast cancer
Introduction: The National Institute of Clinical Excellence (NICE) currently recommends using the 21-gene Oncotype DX assay to help guide decisions about chemotherapy (CT) after surgery in some patients with lymph node negative early breast cancer. There is growing evidence to suggest that the test may also provide useful guidance in patients with limited nodal involvement.This study looked at our institution's experience. Methods Retrospective analysis of all data submitted for Oncotype DX testing in node positive patients by Great Western Hospital up to August 2018. Results: Twenty patients from Great Western Hospital underwent Oncotype DX testing as part of the PONDX trial. Twelve patients had a recurrence score of <18, four patients had recurrence scores in the range 18-30 and only four patients had recurrence scores of >30.Our Breast Multidisciplinary Team (MDT) had recommended both chemotherapy (CT) and Hormone Therapy (HT) for all twenty patients prior to Oncotype DX testing.In view of individual test results, the MDT revised their recommendations to HT treatment only in fourteen cases.When patients were given the opportunity to discuss their results and recommendations only five patients ultimately decided to undertake both CT and HT. Conclusions: The PONDx recurrence score provides critical information over the standard clinical and pathological parameters used to determine CT treatment in node positive patients.Chemotherapy was avoided in 75% of patients after which future analysis aims to quantify the expected cost savings and reduction in patient morbidity.
Topic: Risk factors for breast cancer
Introduction: The National Institute of Clinical Excellence (NICE) currently recommends using the 21-gene Oncotype DX assay to help guide decisions about chemotherapy (CT) after surgery in some patients with lymph node negative early breast cancer. There is growing evidence to suggest that the test may also provide useful guidance in patients with limited nodal involvement.This study looked at our institution's experience. Methods Retrospective analysis of all data submitted for Oncotype DX testing in node positive patients by Great Western Hospital up to August 2018. Results: Twenty patients from Great Western Hospital underwent Oncotype DX testing as part of the PONDX trial. Twelve patients had a recurrence score of <18, four patients had recurrence scores in the range 18-30 and only four patients had recurrence scores of >30.Our Breast Multidisciplinary Team (MDT) had recommended both chemotherapy (CT) and Hormone Therapy (HT) for all twenty patients prior to Oncotype DX testing.In view of individual test results, the MDT revised their recommendations to HT treatment only in fourteen cases.When patients were given the opportunity to discuss their results and recommendations only five patients ultimately decided to undertake both CT and HT. Conclusions: The PONDx recurrence score provides critical information over the standard clinical and pathological parameters used to determine CT treatment in node positive patients.Chemotherapy was avoided in 75% of patients after which future analysis aims to quantify the expected cost savings and reduction in patient morbidity.
P145
Topic: Risk factors for breast cancer
Introduction: The National Institute of Clinical Excellence (NICE) currently recommends using the 21-gene Oncotype DX assay to help guide decisions about chemotherapy (CT) after surgery in some patients with lymph node negative early breast cancer. There is growing evidence to suggest that the test may also provide useful guidance in patients with limited nodal involvement.This study looked at our institution's experience. Methods Retrospective analysis of all data submitted for Oncotype DX testing in node positive patients by Great Western Hospital up to August 2018. Results: Twenty patients from Great Western Hospital underwent Oncotype DX testing as part of the PONDX trial. Twelve patients had a recurrence score of <18, four patients had recurrence scores in the range 18-30 and only four patients had recurrence scores of >30.Our Breast Multidisciplinary Team (MDT) had recommended both chemotherapy (CT) and Hormone Therapy (HT) for all twenty patients prior to Oncotype DX testing.In view of individual test results, the MDT revised their recommendations to HT treatment only in fourteen cases.When patients were given the opportunity to discuss their results and recommendations only five patients ultimately decided to undertake both CT and HT. Conclusions: The PONDx recurrence score provides critical information over the standard clinical and pathological parameters used to determine CT treatment in node positive patients.Chemotherapy was avoided in 75% of patients after which future analysis aims to quantify the expected cost savings and reduction in patient morbidity.
Topic: Risk factors for breast cancer
Introduction: The National Institute of Clinical Excellence (NICE) currently recommends using the 21-gene Oncotype DX assay to help guide decisions about chemotherapy (CT) after surgery in some patients with lymph node negative early breast cancer. There is growing evidence to suggest that the test may also provide useful guidance in patients with limited nodal involvement.This study looked at our institution's experience. Methods Retrospective analysis of all data submitted for Oncotype DX testing in node positive patients by Great Western Hospital up to August 2018. Results: Twenty patients from Great Western Hospital underwent Oncotype DX testing as part of the PONDX trial. Twelve patients had a recurrence score of <18, four patients had recurrence scores in the range 18-30 and only four patients had recurrence scores of >30.Our Breast Multidisciplinary Team (MDT) had recommended both chemotherapy (CT) and Hormone Therapy (HT) for all twenty patients prior to Oncotype DX testing.In view of individual test results, the MDT revised their recommendations to HT treatment only in fourteen cases.When patients were given the opportunity to discuss their results and recommendations only five patients ultimately decided to undertake both CT and HT. Conclusions: The PONDx recurrence score provides critical information over the standard clinical and pathological parameters used to determine CT treatment in node positive patients.Chemotherapy was avoided in 75% of patients after which future analysis aims to quantify the expected cost savings and reduction in patient morbidity.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}